Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.55 |
| ▸ | HTT | P42858 | 8/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10191863 | 0.92 | ALDH1A1 (0.44) | MAPTALDH1A1HTTLMNAPKM | |
| SCHEMBL5576861 | 0.91 | ALDH1A1 (0.59) | MAPTALDH1A1HTTLMNAPKM | |
| SCHEMBL16317557 | 0.85 | MAPT (0.37) | MAPTALDH1A1HTTLMNANPSR1 | |
| SCHEMBL4060483 | 0.79 | ALDH1A1 (0.37) | MAPTALDH1A1HTTLMNAPKM | |
| SCHEMBL4249330 | 0.76 | ALDH1A1 (0.46) | MAPTALDH1A1HTTLMNAPKM | |
| SCHEMBL4281505 | 0.71 | ALDH1A1 (1.00) | MAPTALDH1A1HTTLMNAPKM | |
| SCHEMBL4070310 | 0.65 | HTT (0.61) | MAPTALDH1A1HTTLMNAPKM | |
| SCHEMBL4062708 | 0.62 | CLK1 (0.93) | MAPTALDH1A1HTTLMNAPKM | |
| SCHEMBL9331087 | 0.61 | CA2 (0.44) | ALDH1A1LMNAPTGS2RAB9AHPGD | |
| 4-Nitrotoluene SCHEMBL28532296 | 0.61 | ACHE (0.56) | MAPTALDH1A1HTTSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927576-B2 | HCV inhibitor and therapeutic agent combinations | PTC Therpeutics, Inc. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8883504-B2 | Cell differentiation suppressing agent, method of culturing cells using the same, culture solution, and cultured cell line | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2014-11-11 | — | — | US | disclosed |
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-8013006-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7868037-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| WO-2010118009-A1 | HCV INHIBITOR AND THERAPEUTIC AGENT COMBINATIONS | PTC THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| EP-1960777-B1 | SERUM-FREE EXPANSION OF CELLS IN CULTURE | CHOONGWAE PHARMA CORP (KR) | 2009-10-21 | — | — | EP | disclosed |
| US-20090155906-A1 | CELL DIFFERENTIATION SUPPRESSING AGENT, METHOD OF CULTURING CELLS USING THE SAME, CULTURE SOLUTION, AND CULTURED CELL LINE | MIYABAYASHI TOMOYUKI | 2009-06-18 | — | — | US | disclosed |
| US-20080096928-A9 | Indole compounds that modify translational control of Hepatitis C virus | PTC THERAPEUTICS, INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080096928-A9 | Indole compounds that modify translational control of Hepatitis C virus | PTC THERAPEUTICS, INC. | 2008-04-24 | — | — | US | disclosed |
| US-20070128669-A1 | Serum-free expansion of cells in culture | INSTITUTE FOR CHEMICAL GENOMICS (US) | 2007-06-07 | — | — | US | disclosed |
| EP-1640449-A1 | CELL DIFFERENTIATION INHIBITING AGENT, CELL CULTURE METHOD USING THE SAME, CULTURE MEDIUM AND CULTURED CELL LINE | Asahi Kasei Kabushiki Kaisha (JP) | 2006-03-29 | — | — | EP | disclosed |
| US-20050153941-A1 | Increasing Stage Specific Embryonic Antigen (SSEA) and Nanog gene levels; culturing a stem cell using a low molecular weight derivative of 2-(phenylazo)-2-(3,4-dihydro-2H-isoquinoline-1-ylidene) or N-phenylindole | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096928-A9 | Indole compounds that modify translational control of Hepatitis C virus | EIF2AK2, INMT, IDO1 | MAPT 3963/4885ALDH1A1 1556/4885HTT 1585/4885 |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | MAPT 4416/4885ALDH1A1 591/4885HTT 3355/4885 |
| US-20050153941-A1 | Increasing Stage Specific Embryonic Antigen (SSEA) and Nanog gene levels; culturing a stem cell using a low molecular weight derivative of 2-(phenylazo)-2-(3,4-dihydro-2H-isoquinoline-1-ylidene) or N-phenylindole | MKI67, ALPG, NES | MAPT 4659/4885ALDH1A1 38/4885HTT 4510/4885 |
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | HAVCR2, SERPINB1, ENPEP | MAPT 4044/4885ALDH1A1 1067/4885HTT 4273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.